Psoriasis during pregnancy: characteristics and important management recommendations

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85
   PubMed Web of Science ®Google Scholar
• Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007;334(7605):1218-20
   PubMed Web of Science ®Google Scholar
• Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67(3):459-77
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Navare T, Gross J, et al. Clinical course of psoriasis during pregnancy. Int J Dermatol 2003;42(7):518-20
   PubMed Web of Science ®Google Scholar
• Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005;141(5):601-6
   PubMedGoogle Scholar
• Boyd AS, Morris LF, Phillips CM, et al. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996;35(3):169-72
   PubMedGoogle Scholar
• Aractingi S, Briand N, Le Danff C, et al. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 2001;159(1):71-7
   PubMedGoogle Scholar
• Christophers E, Mrowietz U. The inflammatory infiltrate in psoriasis. Clin Dermatol 1995;13(2):131-5
   PubMedGoogle Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin 2015;33(1):13-23
   PubMed Web of Science ®Google Scholar
• Vogel U, Denecke B, Troyanovsky SM, et al. Transcriptional activation of psoriasis-associated cytokeratin K17 by interferon-gamma. Analysis of gamma-interferon activation sites. Eur J Biochem 1995;227(1-2):143-9
   PubMedGoogle Scholar
• Yip L, McCluskey J, Sinclair R. Immunological aspects of pregnancy. Clin Dermatol 2006;24(2):84-7
   PubMedGoogle Scholar
• Mowad CM, Margolis DJ, Halpern AC, et al. Hormonal influences on women with psoriasis. Cutis 1998;61(5):257-60
   PubMedGoogle Scholar
• McHugh NJ, Laurent MR. The effect of pregnancy on the onset of psoriatic arthritis. Br J Rheumatol 1989;28(1):50-2
   PubMedGoogle Scholar
• McNeill ME. Multiple pregnancy-induced remissions of psoriatic arthritis: case report. Am J Obstet Gynecol 1988;159(4):896-7
   PubMedGoogle Scholar
• Nolten WE, Rueckert PA. Elevated free cortisol index in pregnancy: possible regulatory mechanisms. Am J Obstet Gynecol 1981;139(4):492-8
   PubMedGoogle Scholar
• Lin HC, Hunnicutt JN, Moustafa FA, et al. Pharmacological treatments in pregnant women with psoriasis in the U.S.A. Br J Dermatol 2014;28(10):13306
   Google Scholar
• Gunther C, Kecskes A, Staks T, et al. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998;11(1):35-42
   PubMedGoogle Scholar
• Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol 2014;59(5):460-4
   PubMedGoogle Scholar
• Edwards MJ, Agho K, Attia J, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A 2003;120A(4):459-63
   PubMedGoogle Scholar
• Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007;197(6):585.e581-7. discussion 683-584
   Google Scholar
• Babalola O, Strober BE. Management of psoriasis in pregnancy. Dermatol Ther 2013;26(4):285-92
   PubMed Web of Science ®Google Scholar
• Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014;70(3):401.e401-14. quiz 415
   Google Scholar
• Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011;165(5):943-52
   PubMed Web of Science ®Google Scholar
• Chi CC, Lee CW, Wojnarowska F, et al. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2009(3):CD007346
   Google Scholar
• Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56(5):335-40
   PubMedGoogle Scholar
• Tremezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermatoendocrinol 2011;3(3):180-6
   PubMedGoogle Scholar
• Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988;119(2):223-30
   PubMedGoogle Scholar
• Miyachi Y, Ohkawara A, Ohkido M, et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol 2002;12(5):463-8
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002;146(3):414-22
   PubMedGoogle Scholar
• Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol 2015;20(10):12790
   Google Scholar
• Ahn CS, Awadalla F, Huang KE, et al. Patterns of vitamin D analog use for the treatment of psoriasis. J Drugs Dermatol 2013;12(8):906-10
   PubMedGoogle Scholar
• Bourke JF, Mumford R, Whittaker P, et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997;37(6):929-34
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Mitsuhashi Y, Kondo S. Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis. J Dermatol 2003;30(11):801-4
   PubMedGoogle Scholar
• Braun GS, Witt M, Mayer V, et al. Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. Int J Dermatol 2007;46(12):1315-17
   PubMedGoogle Scholar
• Calcitriol [package insert]. Galderma Laboratories, L.P; Fort Worth, Texas: 2012
   Google Scholar
• Suzuki T, Uchiyama H, Koike Y, et al. [Reproductive and developmental toxicity studies of calcipotriol (MC903): (1)–A fertility study in rats by subcutaneous administration]. J Toxicol Sci 1996;21(Suppl 2):389-401
   PubMedGoogle Scholar
• Dovonex [package insert]. Leo Pharma, Inc., Parsippany, NJ; 2009
   Google Scholar
• Lieben L, Stockmans I, Moermans K, et al. Maternal hypervitaminosis D reduces fetal bone mass and mineral acquisition and leads to neonatal lethality. Bone 2013;57(1):123-31
   PubMedGoogle Scholar
• Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141(1):103-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51(5):723-30
   PubMed Web of Science ®Google Scholar
• Liao YH, Chiu HC, Tseng YS, et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007;157(5):1005-12
   PubMed Web of Science ®Google Scholar
• Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg 2014;18(1):8-14
   PubMed Web of Science ®Google Scholar
• Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther 2009;16(3):264-73
   PubMedGoogle Scholar
• Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol 2007;6(2):185-93
   PubMedGoogle Scholar
• Graham-Brown RA, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003;57(4):319-27
   PubMedGoogle Scholar
• Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001;32(2):207-8
   PubMedGoogle Scholar
• Thomson MA, Hamburger J, Stewart DG, et al. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat 2004;15(5):308-14
   PubMedGoogle Scholar
• Pitarch G, Torrijos A, Mahiques L, et al. Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. Acta Derm Venereol 2006;86(1):64-5
   PubMedGoogle Scholar
• Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol 2004;150(5):1052-3
   PubMedGoogle Scholar
• Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000;70(12):1718-21
   PubMed Web of Science ®Google Scholar
• Jain AB, Reyes J, Marcos A, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation 2003;76(5):827-32
   PubMed Web of Science ®Google Scholar
• Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996;30(9):935-40
   PubMed Web of Science ®Google Scholar
• Schwarb FP, Gabard B, Rufli T, et al. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology 1999;198(1):44-51
   PubMed Web of Science ®Google Scholar
• Brubacher JR, Hoffman RS. Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol 1996;34(4):431-6
   PubMed Web of Science ®Google Scholar
• Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle) 2002;14(2):188-90
   PubMedGoogle Scholar
• Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155(1):26-31
   PubMedGoogle Scholar
• Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187(6):1623-30
   PubMed Web of Science ®Google Scholar
• Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 2014;26(3):334-40
   PubMed Web of Science ®Google Scholar
• Torloni MR, Cordioli E, Zamith MM, et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound Obstet Gynecol 2006;27(2):227-9
   PubMedGoogle Scholar
• Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59(2):295-315
   PubMed Web of Science ®Google Scholar
• Zhu JL, Hjollund NH, Andersen AM, et al. Occupational exposure to pesticides and pregnancy outcomes in gardeners and farmers: a study within the Danish National Birth Cohort. J Occup Environ Med 2006;48(4):347-52
   PubMedGoogle Scholar
• Vun YY, Jones B, Al-Mudhaffer M, et al. Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids. J Am Acad Dermatol 2006;54(2 Suppl):S28-30
   PubMedGoogle Scholar
• Masmoudi A, Abdelmaksoud W, Ghorbel S, et al. [Impetigo herpetiformis (two cases)]. J Gynecol Obstet Biol Reprod (Paris) 2008;37(8):804-7
   PubMedGoogle Scholar
• Jang MS, Baek JW, Kang DY, et al. Successful treatment with narrowband UVB phototherapy in prurigo pigmentosa associated with pregnancy. Eur J Dermatol 2011;21(4):634-5
   PubMedGoogle Scholar
• Bozdag K, Ozturk S, Ermete M. A case of recurrent impetigo herpetiformis treated with systemic corticosteroids and narrowband UVB. Cutan Ocul Toxicol 2012;31(1):67-9
   PubMed Web of Science ®Google Scholar
• Zeichner JA. Narrowband UV-B phototherapy for the treatment of acne vulgaris during pregnancy. Arch Dermatol 2011;147(5):537-9
   PubMedGoogle Scholar
• El-Saie LT, Rabie AR, Kamel MI, et al. Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis. Lasers Med Sci 2011;26(4):481-5
   PubMedGoogle Scholar
• Rose RF, Batchelor RJ, Turner D, et al. Narrowband ultraviolet B phototherapy does not influence serum and red cell folate levels in patients with psoriasis. J Am Acad Dermatol 2009;61(2):259-62
   PubMedGoogle Scholar
• Yentzer BA, Gustafson CJ, Feldman SR. Explicit and implicit copayments for phototherapy: examining the cost of commuting. Dermatol Online J 2013;19(6):18563
   PubMedGoogle Scholar
• Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011;65(4):699-714. quiz 715
   PubMedGoogle Scholar
• Bredberg A, Lambert B. Induction of SCE by DNA cross-links in human fibroblasts exposed to 8-MOP and UVA irradiation. Mutat Res 1983;118(3):191-204
   PubMedGoogle Scholar
• Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991;127(3):347-50
   PubMedGoogle Scholar
• Gunnarskog JG, Kallen AJ, Lindelof BG, et al. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 1993;129(3):320-3
   PubMedGoogle Scholar
• Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res Part A Clin Mol Teratol 2012;94(4):187-207
   PubMed Web of Science ®Google Scholar
• Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47(6):533-9
   PubMedGoogle Scholar
• Donnenfeld AE, Pastuszak A, Noah JS, et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49(2):79-81
   PubMedGoogle Scholar
• Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88(6):589-92
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85
   PubMed Web of Science ®Google Scholar
• David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988;3(4):273-88
   PubMedGoogle Scholar
• Brindley CJ. Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). Dermatologica 1989;178(2):79-87
   PubMedGoogle Scholar
• Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71(8):1051-5
   PubMed Web of Science ®Google Scholar
• Lamarque V, Leleu MF, Monka C, et al. Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 1997;29(5):2480
   PubMedGoogle Scholar
• Armenti VT, Ahlswede KM, Ahlswede BA, et al. Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1995;59(4):476-9
   PubMed Web of Science ®Google Scholar
• Sgro MD, Barozzino T, Mirghani HM, et al. Pregnancy outcome post renal transplantation. Teratology 2002;65(1):5-9
   PubMedGoogle Scholar
• Miniero R, Tardivo I, Curtoni ES, et al. Outcome of pregnancy after organ transplantation: a retrospective survey in Italy. Transpl Int 2005;17(11):724-9
   PubMedGoogle Scholar
• Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91(5):2144-9
   PubMedGoogle Scholar
• Solomon CG, Greene MF. Control of hypertension in pregnancy–if some is good, is more worse? N Engl J Med 2015;372(5):475-6
   PubMedGoogle Scholar
• Thomas AG, Burrows L, Knight R, et al. The effect of pregnancy on cyclosporine levels in renal allograft patients. Obstet Gynecol 1997;90(6):916-19
   PubMedGoogle Scholar
• Wright S, Glover M, Baker H. Psoriasis, cyclosporine, and pregnancy. Arch Dermatol 1991;127(3):426
   PubMedGoogle Scholar
• Kapoor R, Kapoor JR. Cyclosporine resolves generalized pustular psoriasis of pregnancy. Arch Dermatol 2006;142(10):1373-5
   PubMedGoogle Scholar
• Edmonds EV, Morris SD, Short K, et al. Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone. Clin Exp Dermatol 2005;30(6):709-10
   PubMedGoogle Scholar
• Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol 2000;142(3):582-4
   PubMed Web of Science ®Google Scholar
• Raddadi AA, Baker Damanhoury Z. Cyclosporin and pregnancy. Br J Dermatol 1999;140(6):1197-8
   PubMedGoogle Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83(12):1583-90
   PubMed Web of Science ®Google Scholar
• Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J 2014;20(5):22608
   PubMedGoogle Scholar
• Otezla [package insert]. Celgene Corporation; Summit, NJ: 2014
   Google Scholar
• Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000;19(4):226-8
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
   PubMed Web of Science ®Google Scholar
• Davies R, Dixon WG, Watson KD, et al. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis 2013;72(3):461-2
   PubMed Web of Science ®Google Scholar
• Mervic L. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Pannonica Adriat 2014;23(2):27-31
   PubMedGoogle Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33(9):1053-8
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3):286-92. quiz e224
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10):1255-8
   PubMed Web of Science ®Google Scholar
• Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford) 2010;49(11):2225-7
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 2009;68(11):1793-4
   PubMed Web of Science ®Google Scholar
• Cheent K, Nolan J, Shariq S, et al. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis 2010;4(5):603-5
   PubMed Web of Science ®Google Scholar
• Djokanovic N, Klieger-Grossmann C, Pupco A, et al. Safety of infliximab use during pregnancy. Reprod Toxicol 2011;32(1):93-7
   PubMed Web of Science ®Google Scholar
• Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006;33(5):1014-17
   PubMed Web of Science ®Google Scholar
• Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36(3):635-41
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL. Was risk properly assessed in Carter, et al’s safety assessment of tumor necrosis factor antagonists during pregnancy? J Rheumatol 2009;36(9):2122; author reply 2123
   PubMedGoogle Scholar
• Rump JA, Schonborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol 2010;69(10):903-9
   PubMedGoogle Scholar
• Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014;43:78-84
   PubMed Web of Science ®Google Scholar
• Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76(1):28-34
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology 2007;46(4):695-8
   PubMed Web of Science ®Google Scholar
• Natsumi I, Matsukawa Y, Miyagawa K, et al. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33(9):2433-5
   PubMedGoogle Scholar
• Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012;41(3):196-201
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4(5):621-30
   PubMed Web of Science ®Google Scholar
• Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54(6):890
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17(9):1846-54
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011;106(2):214-23. quiz 224
   PubMed Web of Science ®Google Scholar
• Mishkin DS, Van Deinse W, Becker JM, et al. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis 2006;12(8):827-8
   PubMedGoogle Scholar
• Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006;51(11):2045-7
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Symmons DP, Watson KD, et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006;54(8):2701-2
   PubMed Web of Science ®Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 2010;89(5):351-63
   PubMed Web of Science ®Google Scholar
• Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012;11(10):1240
   PubMed Web of Science ®Google Scholar
• Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol 2014;21(10):12872
   Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012;6(4):105-7
   PubMedGoogle Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014;371(4):326-38
   PubMed Web of Science ®Google Scholar
• Cosentyx [package insert]. Novartis Pharmaceuticals Corporation; East Hanover, NJ: 2015
   Google Scholar
• Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Food and Drug Administration, 2008
   Google Scholar